0
Articles |

Phospho-Akt Overexpression in Non-small Cell Lung Cancer Confers Significant Stage-Independent Survival Disadvantage*

Odile David, MD; Helena LeBeau, HT(ASCP); Arnold R. Brody, PhD; Mitchell Friedman, MD, FCCP; James Jett, MD, FCCP
Author and Funding Information

*From the Department of Pathology (Drs. David and Brody, and Ms. LeBeau) and the Section of Pulmonary, Critical Care, and Environmental Medicine (Dr. Friedman), Tulane University School of Medicine, New Orleans, LA; and the Division of Pulmonary Medicine (Dr. Jett), Mayo Clinic, Rochester, MN.

Correspondence to: Odile David, MD, Assistant Professor of Pathology, Tulane University School of Medicine, 1430 Tulane Ave, SL79, New Orleans, LA 70112; e-mail: odavid@tulane.edu



Chest. 2004;125(5_suppl):152S. doi:10.1378/chest.125.5_suppl.152S-a
Text Size: A A A
Published online

Extract

Akt is a signal transduction protein that, when activated at the cytoplasmic membrane, plays a central role in inhibiting apoptosis in a variety of cell types, including human cancer cells, from many different sites of origin. In cell lines derived from human non-small cell lung cancers (NSCLCs), Akt has been shown to confer chemoresistance by the inhibition of apoptosis in response to many different chemotherapeutic agents including platinum-based agents, which are often the first-line therapy for NSCLCs. Less than 50% of patients with NSCLC treated with chemotherapy have clinical evidence of a response.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543